Remdesivir News and Research

RSS

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

This scanning electron microscope image shows SARS-CoV-2 (round gold particles) emerging from the surface of a cell cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19.NIAID

28 Jan 2022

Hospitalized COVID-19 patients may derive modest benefit from convalescent plasma, study shows

Transfusions of blood plasma donated by people who have recovered from COVID-19 may help patients hospitalized with the virus, a new international study shows.

25 Jan 2022

Study explains why Omicron infections are less likely to cause severe disease

A new study by researchers from the University of Kent and the Goethe University Frankfurt shows that the SARS-CoV-2 Omicron variant is less effective than Delta at blocking a cellular defense mechanism against viruses, the so-called “interferon response”.

24 Jan 2022

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United States Food and Drug Administration (FDA) for their in vitro potency against several SARS-CoV-2 variants, including the currently dominant Omicron train.

23 Jan 2022

Patient, beware: Some states still pushing ineffective covid antibody treatments

As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that federal health officials warn no longer work against the highly contagious version of the virus that causes covid-19.

21 Jan 2022

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

A recent study, currently available on bioRxiv* preprint server, shows that a novel protease inhibitor known as nirmatrelvir has potent activity against Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also other variants evaluated in this paper – which supports its potential role in reducing the disease burden from coronavirus disease 2019 (COVID-19).

21 Jan 2022

SARS-CoV-2 Omicron infections milder in children compared to Delta

The clinical severity of COVID-19 was found to be lower in children younger than five years of age after the emergence of SARS-CoV-2 Omicron variant.

20 Jan 2022

Variants of SARS-CoV-2 and preventive strategies

A recent review article published in the journal Advanced Science reviewed the features of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants. Using a physical and materials science perspective, the review also summarizes the most significant variants of SARS-CoV-2 encountered to date as well as possible preventive strategies.

19 Jan 2022

The latest advancements in polymer-based nanotechnology approaches used to fight against SARS-CoV-2

A recent review discusses the engineering versatility of polymeric nanoparticles - making a good therapeutic alternative against coronavirus diseases.

19 Jan 2022

Macrodomains represent a unique target for pathogens with pandemic potential

In a new study published in the journal Pathogens, researchers have summarized the role of the macrodomain in viral replication and virulence and further reviewed the development of macrodomain inhibitors as antiviral agents.

18 Jan 2022

New findings support the routine use of remdesivir in hospitalized COVID-19 patients

Remdesivir, an antiviral drug used to treat COVID-19, increased the likelihood of clinical improvement in COVID-19 patients on low-flow oxygen or no oxygen, according to a new study authored by the Johns Hopkins University School of Medicine, the Johns Hopkins Bloomberg School of Public Health, HCA Healthcare, and Genospace.

18 Jan 2022

Topical antiseptic Acriflavine inhibits SARS-CoV-2 and other betacoronaviruses

A new study, published in the journal Cell Chemical Biology, has reported the discovery of acriflavine (ACF), an effective inhibitor of SARS-CoV-2. This drug is a mixture of trypaflavines (3,6-diamino-10-methylacridinium chloride and 3,6-diamino-3-methylacridinium chloride) and proflavine (3,6-diaminoacridine).

16 Jan 2022

Impact of post-exposure BNT162b2 prophylaxis against SARS-CoV-2 infections

In a new study, researchers determined evidence for post-exposure vaccination in reducing the mortality rate of COVID-19 and concluded that post-exposure prophylaxis successfully decreased SARS-CoV-2-associated death rates.

11 Jan 2022

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

Researchers developed a human A549 lung epithelial cell-based model to probe SARS-CoV-2 replication.

9 Jan 2022

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

New research shows evidence that the Omicron variant is less severe compared to the Delta variant.

6 Jan 2022

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

The LIVE-AIR phase 3 clinical trial is associated with early treatment of hyperinflammatory response with the humanized monoclonal antibody lenzilumab in COVID-19 patients with decreased oxygen saturation. The study results are posted to the medRxiv* preprint server.

6 Jan 2022

Statistical analysis reveals less severe COVID-19 outcome due to Omicron variant

A new study demonstrated that in the US, the COVID-19 cases arising after the emergence of the SARS-CoV-2 Omicron variant showed reduced severity of infection than in the cases recorded in previous time points (during the Delta variant outbreak).

5 Jan 2022

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

An independent study confirms that current and prospective antiviral treatments are effective in inhibiting severe infection from SARS-CoV-2.

4 Jan 2022

Study suggests nitazoxanide fails to reduce the severity of SARS-CoV-2

A new study shows that the optimization of nitazoxanide formulations may allow the review of the potential use of the drug for the treatment of SARS-CoV-2 infection.

22 Dec 2021

New oral pill for COVID-19 home treatment

As cases and hospitalizations continue to rise in many countries, new treatments are being sought to arrest the progression of the disease, preventing severe illness and death or disability. One such is the small molecule molnupiravir, the focus of a new research paper.

20 Dec 2021